ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1831

Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus

Konstantinos Tselios1, Dafna Gladman2, Jiandong Su2, Olga Ace3, Arthy Sabapathy3, Anne MacKinnon3 and Murray Urowitz4,5, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: coronary artery disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We previously reported the influence of traditional and disease-related risk factors on the development of cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE) followed for 7 years.  The aim of this study was to further investigate their impact on clinical CVD in SLE patients and controls after 15 years of follow-up.

Methods: Two hundred and fifty women with SLE and no prior history of CVD (age 44.5±12 years, disease duration 13.7±9.7 years) and 250 age-matched healthy women (age 44.1±14 years) were recruited between 1998 and 2000. Recorded risk factors at baseline included arterial hypertension, diabetes mellitus, dyslipidemia (total cholesterol, triglycerides, HDL, LDL, VLDL), smoking, family history of premature CVD and body mass index. Patients and controls were prospectively followed for 14±4.1 and 15.9±1.9 years respectively for the development of cardiovascular events (CVEs). CVEs included angina pectoris, myocardial infarction (MI, fatal and non-fatal) transient ischemic attack (TIA), stroke (fatal and non-fatal), and were recorded at clinic visit for patients and by interview and chart review for controls. Statistical software SAS (version 9.3) was used for analysis; p<0.05 was considered significant.

Results: Initial risk factor profile revealed a higher prevalence of arterial hypertension (83/250, 33.2% vs 32/250, 12.8%, p<0.001) and diabetes mellitus (12/250, 4.8% vs 2/250, 0.8%, p=0.007) in patients’ group. The frequency of other variables did not differ significantly. Follow-up data, after 15 years, were available for 211 patients and 137 controls. There were 32 deaths in SLE patients and 7 in controls. CVEs occurred in 32/179 patients (17.9%) and 8/130 controls (6.2%), Table 1. Angina and MI were more common in SLE than controls (17/211, 12.8% vs. 9/137, 6.5%, p=0.005). There were no statistically significant differences for TIA and stroke.

 

Angina

MI

(non-fatal)

MI (fatal)

TIA

Stroke (non-fatal)

Stroke (fatal)

SLE (n=211)

N (%)

17

(8.1%)

10

(4.7%)

6

(2.8%)

4

(1.9%)

5

(2.4%)

2

(0.9%)

Controls (n=137)

 

4

(2.9%)

5

(3.6%)

0

(0%)

2

(1.5%)

1

 (0.7%)

0

(0%)

Multivariate Cox-regression analysis demonstrated SLE [HR=2.89, 95% CI 1.22-6.81], family history [HR=2.25, 95% CI 1.13-4.45], triglycerides [HR=1.45, 95 CI 1.03-2.02], 10-year Framingham score [HR=1.12, 95% CI 1.05-1.19] and serum creatinine [HR=1.01 95% CI (1.0-1.02)] to be important predictors for CVEs. Patients with SLE with CVEs compared to those without were older (47.6±9.6 vs. 41.5±10.6 years, p=0.003), had higher serum creatinine (94.7±59.4 vs. 75.4±23.2 μmol/L, p=0.003) and, more frequently, hypertension (43.8% vs. 24.5%, p=0.028), hypercholesterolemia (46.9% vs. 27.9%, p=0.036) and family history of CVD (56.3% vs. 34%, p=0.019). 

Conclusion: SLE patients have a 3-fold increased risk for clinical CVD as compared to healthy controls in the long term. Coronary heart disease was significantly more frequent than cerebrovascular disease. SLE itself, as well as traditional risk factors, are important predictors for CVEs.


Disclosure: K. Tselios, None; D. Gladman, None; J. Su, None; O. Ace, None; A. Sabapathy, None; A. MacKinnon, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman D, Su J, Ace O, Sabapathy A, MacKinnon A, Urowitz M. Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/initial-risk-factor-profile-and-long-term-cardiovascular-outcome-in-women-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/initial-risk-factor-profile-and-long-term-cardiovascular-outcome-in-women-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology